Advanced Small Animal Ultrasound Imaging - Vevo F2

先进的小动物超声成像 - Vevo F2

• 批准号: 10632878
• 负责人: Timothy McKinsey
• 金额: $ 45.47万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-05 至 2024-06-04
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10632878
• 关键词: Animals; Applications Grants; Area; Basic Science; Biomedical Research; Blood Vessels; Blood flow; Cardiac; Cardiology; Cardiorenal syndrome; Cardiovascular Models; Cardiovascular system; Cells; Clinical; Collaborations; Colorado; Core Facility; Data; Disease; Fee-for-Service Plans; Funding; Goals; Heart; Human; Impairment; Inferior; Injections; Kidney; Lung; Measurement; Medical; Medical center; Medicine; Metabolic; Metabolic Diseases; Modeling; Monitor; Mus; Neoplasm Metastasis; Operating System; Pancreas; Pathogenesis; Pediatric Hospitals; Portal vein structure; Pre-Clinical Model; Rattus; Request for Proposals; Research; Research Personnel; Resolution; Rodent Model; Role; Science; Services; Structure; System; Technology; Testing; Therapeutic; Therapeutic Agents; Translating; Translations; Ultrasonography; United States National Institutes of Health; Universities; animal facility; biomarker discovery; contrast imaging; equipment acquisition; human disease; imaging system; innovation; instrument; metropolitan; novel therapeutics; pathogen; pre-clinical; right ventricular remodeling; tool; tumor; ultrasound

PROJECT SUMMARY/ABSTRACT This proposal requests funds for the acquisition of a state-of-the-art Vevo F2 high-resolution ultrasound imaging system (FujiFilm-VisualSonics). This system would be integrated into and managed by the Pre-Clinical Cardiovascular (PCC) Core facility within the Division of Cardiology/Department of Medicine at the University of Colorado Denver Anschutz Medical Campus (AMC). Due to the highly advanced technology of the Vevo F2, this system would significantly expand the current capabilities of the PCC Core and would enhance on-going, system-wide collaborations at the University of Colorado. The long-term objective of this proposal is to provide advanced ultrasound capabilities that lead to a more detailed understanding of pathophysiological mechanisms and highlight potential therapeutic strategies that could be translated into innovative treatments for human diseases. Our goal is to do the best science possible and be guided by the data. Having a Vevo F2 instrument in our PCC Core would undoubtedly help us achieve this goal. A major focus of the PCC Core to facilitate studies employing mouse and rat models of cardiovascular, pulmonary, renal, metabolic and onocologic diseases. Our ultimate goal is to translate findings made in these pre-clinical models into novel therapeutics for the treatment of devastating diseases in humans. We collaborate closely with research groups across the campus, and the entire Denver metropolitan area, to understand the roles of heart:kidney and heart:lung cross-talk in the pathogenesis of cardiorenal disease and pulmonary vascular/right ventricular remodeling. Additionally, we have collaborations focused on vascular stiffening, impaired blood flow, metabolic disease, tumor metastasis, biomarker discovery and contrast imaging in rodent models (see Figure). All of these efforts would benefit from the acquisition of a Vevo F2 instrument, which would enable state-of-the-art, non-invasive, longitudinal measurements of cardiac structure and function, renal, cardiac and pancreatic blood flow, and tumor formation in mouse and rat models. In addition, this high-definition ultrasound system would provide an invaluable tool for monitoring localized delivery of cells and therapeutic agents via intra-cardiac or portal vein injection. The Vevo F2, which has many features in common with clinical instruments, would have a tremendous impact on NIH-funded research at the University of Colorado Anschutz Medical Campus, and has the potential to facilitate translation of basic science discoveries into innovative treatments for human disease. In addition to the aforementioned collaborations, through fee-for-service arrangements, the PCC Core serves a diverse group of investigators, not only on the AMC, which has two separate animal facilities, but also in the Colorado Children's Hospital, the Rocky Mountain Regional VA Medical Center, and University of Colorado Boulder. We are also deeply committed to assisting early stage investigators obtain preliminary data to support their first NIH grant applications. For all of these studies we employ two Vevo 2100 instruments, which are located in a pathogen-free animal facility in Research Center 2 (RC2). The upgrade to the Vevo F2 is crucially needed to meet the increasing demands, and technical needs, of a multitude of projects, which have tested the limits of the Vevo 2100 instruments that we purchased in 2014. Not only is the technology of this instrument inferior to that of the Vevo F2, but the Vevo 2100 will no longer be serviced by FujiFilm-VisualSonics starting in 2023. Furthermore, the Vevo 2100 uses a Windows XP operating system, which is not compatible with the IT requirements of the University of Colorado. It is essential that we obtain a Vevo F2 to maintain and promote cutting edge biomedical research at the University of Colorado.

项目摘要/摘要 该提案要求资金获得最先进的VEVO F2高分辨率超声成像 系统（Fujifilm-Visualsonics）。该系统将被临床前整合并管理 心脏血管（PCC）核心设施内的心脏病学系/医学系 科罗拉多州丹佛Anschutz医疗校园（AMC）。由于VEVO F2的高级技术， 该系统将大大扩大PCC核心的当前功能，并增强持续的， 科罗拉多大学的系统范围合作。该提议的长期目标是提供 高级超声功能，导致对病理生理机制的更详细的了解 并强调了可以转化为人类创新治疗的潜在治疗策略 疾病。我们的目标是做最好的科学，并受到数据的指导。拥有VEVO F2乐器 在我们的PCC中，核心无疑将帮助我们实现这一目标。 PCC核心的主要重点是促进使用小鼠和大鼠心血管模型的研究 肺，肾脏，代谢和内源疾病。我们的最终目标是翻译这些发现 临床前模型进入新的治疗人类毁灭性疾病的治疗方法。我们合作 与整个校园以及整个丹佛都会区的研究小组紧密相关，以了解 心脏的角色：肾脏和心脏：心脏疾病和肺部发病机理中的肺部串扰 血管/右心室重塑。此外，我们还集中于血管僵硬， 血液流量受损，代谢疾病，肿瘤转移，生物标志物发现和啮齿动物的对比成像 模型（见图）。所有这些努力将受益于获取VEVO F2仪器，这将 启用心脏结构和功能的最先进的，无创的，纵向测量，肾脏，心脏 小鼠和大鼠模型中的胰腺血流以及肿瘤形成。此外，这个高清 超声系统将为监测细胞的局部递送和治疗性提供宝贵的工具 通过海内或门静脉注射的代理。这 VEVO F2，它具有许多共同的功能 临床仪器将产生巨大影响 关于科罗拉多大学NIH资助的研究 Anschutz医疗校园，有可能 促进基础科学发现转化为 人类疾病的创新治疗方法。 除了上述合作之外， 通过支付服务安排，PCC核心 为一群调查人员提供服务，不仅在 AMC有两个独立的动物设施，但 同样在科罗拉多州儿童医院，岩石 山区VA医疗中心和大学 科罗拉多博尔德。我们也非常投入 协助早期调查人员获得 初步数据以支持他们的第一个NIH赠款 申请。对于所有这些研究，我们都采用了两个 Vevo 2100仪器，位于 研究中心的无病原体动物设施2 （RC2）。 VEVO F2的升级至关重要 需要满足日益增长的需求，并且 技术需求，多种项目 测试了我们的VEVO 2100仪器的极限 在2014年购买。不仅技术 仪器低于VEVO F2，但VEVO 从2023年开始，2100将不再由Vujifilm-Visualsonics服务。此外，Vevo 2100使用 Windows XP操作系统与科罗拉多大学的IT要求不兼容。 我们必须获得VEVO F2以维持和​​促进尖端生物医学研究至关重要 科罗拉多大学。